SCHEMBL4180853

SCHEMBL4180853

COc1cc(OC)cc(-c2nnc(-c3cccnc3C(N)c3cccnc3)[nH]2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.40
NPY5R Q15761 2/20 0.39
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
RIPK1 Q13546 1/20 0.35
CCNB3 Q8WWL7 1/20 0.35
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
MGAT2 Q10469 1/20 0.34
AURKA O14965 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
ALOX15 P16050 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4172618 0.92 KCNA5 (0.48) KCNA5NPY5RCCNB2CDK1CCNB1
SCHEMBL4175489 0.86 NPY5R (0.47) NPY5RCCNB2CDK1CCNB1CCNB3
SCHEMBL4182605 0.81 AURKA (0.45) KCNA5NPY5RCCNB2CDK1CCNB1
SCHEMBL4178005 0.80 MAPT (0.39) KDM4EAURKADYRK1A
SCHEMBL4186196 0.80 TUBB4A (0.42) KCNA5NPY5RDYRK1A
SCHEMBL4173385 0.78 ALDH1A1 (0.41) KDM4EALDH1A1NPSR1CYP1A2CYP3A4
SCHEMBL4181134 0.78 KDM4E (0.44) KDM4EHSD17B10ALDH1A1CYP1A2CYP3A4
SCHEMBL4180993 0.78 PTGS2 (0.47)
SCHEMBL4171111 0.74 TEK (0.44) HSD17B10ALDH1A1HPGDCYP1A2CYP1A1
SCHEMBL4180867 0.72 CYP3A4 (0.57) KDM4EHSD17B10ALDH1A1HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
WO-2005004818-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL KCNA5 4377/4885NPY5R 4592/4885CCNB2 277/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL KCNA5 4377/4885NPY5R 4592/4885CCNB2 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.